Compound Notes 4 min read
GHK-Cu: How a Copper Tripeptide From Human Plasma Became a Skin Compound
A history of GHK-Cu from its 1973 isolation in human plasma to the modern skin and connective-tissue research that put it on the protocol radar, and what the published work actually supports.
Last reviewed: May 2026
In 1973, a young biochemist named Loren Pickart was working on a question about why young blood plasma seemed to support better tissue regeneration in cell culture than older plasma did. He isolated and characterised a small tripeptide, glycyl-L-histidyl-L-lysine, that turned out to do a meaningful share of the work. When the tripeptide bound a copper ion, the activity increased substantially. The compound became known as GHK-Cu. Five decades later it is one of the better-studied small peptides in the cosmetic and connective-tissue literature, and the path from plasma curiosity to modern protocol takes some explaining.
The original observation
Pickart’s group at the University of California established that GHK-Cu copper-binding capacity was central to its activity. The tripeptide alone has weak signalling effects. The copper-bound form interacts with a specific set of cellular receptors and enzymes involved in connective tissue maintenance. Through the 1970s and 1980s, multiple labs replicated the basic finding: GHK-Cu promotes fibroblast activity, supports collagen and elastin synthesis, and modulates the inflammatory environment around healing tissue. These were cell-culture and animal observations. The translation to human use took another decade.
The cosmetic chemistry detour
By the late 1980s, cosmetic-chemistry companies had recognised that a peptide which supported fibroblast activity and collagen synthesis was relevant to skin-aging products. GHK-Cu found its first commercial home in topical skincare formulations. The compound proved reasonably stable in topical vehicles, penetrated the stratum corneum modestly, and produced visible improvements in fine lines and skin texture in well-controlled human trials. The cosmetic-chemistry literature on GHK-Cu through the 1990s and 2000s is more developed than the peptide-research literature most consumers encounter today.
The skincare market settled on GHK-Cu as a credible mid-range active. Not as dramatic as retinoids. Not as well-marketed as hyaluronic acid. A working compound with a real mechanism, used in serums priced at the upper end of the mass market and the lower end of the luxury tier.
The longevity-research return
The peptide-research conversation rediscovered GHK-Cu around 2012, when a series of papers expanded the activity profile beyond skin. Beyond fibroblast support, GHK-Cu modulates copper-dependent enzymes throughout the body. It interacts with antioxidant pathways. It has documented effects on hair follicle stem cells, supporting research interest in androgenetic-alopecia contexts. Its anti-inflammatory profile in animal models extended its plausibility into broader connective-tissue work.
The injectable peptide-research conversation that followed runs in parallel to the topical cosmetic conversation. Subcutaneous research-protocol dosing produces systemic exposure that topical use does not. The mechanisms are similar but the operational pattern is different. Researchers running soft-tissue or skin protocols now often combine topical application for the local site and subcutaneous protocols for systemic support.
What the modern protocol picture looks like
GHK-Cu sits in a specific niche in the recovery-and-longevity stack. It is not as broadly studied as BPC-157 for soft-tissue work. It is not as well-characterised as the GH-pulse compounds for body composition. Its strongest evidence base is in skin, hair, and connective-tissue contexts, with a secondary case in broader anti-inflammatory and copper-dependent enzyme support.
Standard research-protocol patterns for subcutaneous GHK-Cu run 1 to 3 mg per administration, two to five times per week, in cycles of 8 to 12 weeks. Topical formulations vary widely in concentration, with cosmetic products typically in the 0.005 to 0.05% range and clinical-research formulations sometimes higher.
Where GHK-Cu earns its place
Three protocol contexts where the compound is most defensible:
- Skin and connective-tissue protocols where collagen support is the goal. The cosmetic-chemistry literature is well-developed and the topical use case is genuinely supported.
- Hair-follicle research contexts. The published work on follicle stem-cell support is preliminary but consistent with the broader copper-peptide story.
- Recovery stacks where a third compound complements BPC-157 (local soft tissue) and TB-500 (systemic cellular migration). GHK-Cu adds the connective-tissue and inflammatory-environment angle.
The compound is research-grade only, sold for laboratory and research use. It is not a medicine and not a licensed dietary supplement.
What pairs with GHK-Cu
- BPC-157 for the local soft-tissue side of recovery work
- Wolverine as the BPC plus TB-500 pre-blend if you want broader coverage
- Nightfall as the supplement layer where sleep architecture supports tissue repair
The Protocol Builder Recovery goal seeds curated stacks that include GHK-Cu where the goal supports it.
The honest framing
GHK-Cu has aged better than most peptides from its era. The mechanism is well-characterised. The research base is real. The cosmetic-industry use case is mature. The protocol use case is reasonable. The compound is not a hero of any stack but it is a credible contributor to several. The fifty-year arc from Pickart’s plasma observation to current use has been, by peptide-research standards, unusually consistent.